Under our new Chairman, Mr Ian Anderson, Resonance Health will focus on the commercial development of the FerriScan® technology and cease its pathology laboratory acquisition strategy. In line with this change of direction the following board members have resigned:
- Dr Gary Pace
- Mr Michael Dalsin
- Mr Roger Greene
The contract with our US based CEO, Mr Ed Dooling, has also been terminated.
The Board thanks them for their substantial time and effort.
Resonance Health is ideally positioned to take advantage of the increasing demand for the quantitative analysis of radiological images in a regulated and quality controlled environment.
The company continues to be commited to the growth of the FerriScan® revenues with a strong focus on cost management, while expanding into new technologies and services complimentary to the skills and infrastructure now firmly established at Resonance Health.
To view a copy of this ASX announcement please click on the investor link in the menu above and then ASX announcements. |
